Autolus Therapeutics (AUTL) EBT (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of EBT data on file, last reported at -$91.5 million in Q4 2025.

• Quarterly EBT fell 250.04% year-over-year to -$91.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$285.6 million (down 30.31% YoY) and the FY2025 annual result came in at -$285.6 million, down 30.31% from the prior year.
• EBT fell to -$91.5 million in Q4 2025, from -$78.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$7.4 million in Q4 2022 to a low of -$91.5 million in Q4 2025.
• A 5-year average of -$49.2 million and a median of -$44.1 million in 2022 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT surged 69.23% — and 2023, when it tumbled 939.1%.
• Tracing AUTL's EBT over 5 years: stood at -$24.1 million in 2021, then surged by 69.23% to -$7.4 million in 2022, then plunged by 939.1% to -$77.2 million in 2023, then jumped by 66.13% to -$26.1 million in 2024, then sank by 250.04% to -$91.5 million in 2025.
• The last three EBT figures came in at -$91.5 million (Q4 2025), -$78.6 million (Q3 2025), and -$47.5 million (Q2 2025), per Business Quant data.